Related Experiment Video

Updated: Aug 24, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Insulin pump therapy for 1-6 year old children with type 1 diabetes

Naim Shehadeh1, Tadej Battelino, Avinoam Galatzer

  • 1Pediatric Diabetes Unit, Meyer Children's Hospital of Haifa, Haifa, Israel. n_shehadeh@rambam.health.gov.il

The Israel Medical Association Journal : IMAJ
|May 21, 2004
PubMed

Insights

Insulin pump therapy is safe and feasible for very young children with type 1 diabetes, significantly improving their quality of life and metabolic control. This treatment option offers benefits for managing pediatric diabetes.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Medical Technology

Background:

  • Managing diabetes in preschool-aged children presents unique challenges for families and healthcare providers.
  • Type 1 diabetes affects a growing number of young children, necessitating effective management strategies.

Purpose of the Study:

  • To evaluate the feasibility and safety of insulin pump therapy in children aged 1-6 years.
  • To assess the impact of insulin pump therapy on quality of life and glycemic control in this pediatric population.

Main Methods:

  • A 12-month study involving 15 children (aged 1-6 years) with type 1 diabetes using insulin pump therapy.
  • Collected data included insulin dosage, HbA1c levels, hypoglycemic events, and quality of life/treatment satisfaction scores.
  • Compared outcomes with previous multiple daily injection (MDI) treatment.

Main Results:

  • Significant reduction in HbA1c levels after 12 months of insulin pump therapy compared to baseline (P < 0.05).
  • No significant differences observed in insulin dose or frequency of hypoglycemic events between pump and MDI therapy.
  • Marked improvements in quality of life (DQOL) and treatment satisfaction (DTSQ) scores with insulin pump use (P < 0.001).

Conclusions:

  • Insulin pump therapy is a feasible and safe treatment option for very young children with type 1 diabetes.
  • This therapy demonstrably enhances the quality of life and glycemic control in this age group.
  • Insulin pump therapy should be considered a viable therapeutic option for pediatric diabetes management.
Abstract

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...